Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update Nov 15, 2016
Xenetic Biosciences Announces Nasdaq Listing of its Common Stock and Pricing of $10M Public Offering Nov 1, 2016
Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen® for Anemia Oct 10, 2016
Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer Aug 19, 2016
Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine Aug 18, 2016
Xenetic Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market Jun 1, 2016
Xenetic Biosciences Appoints Renowned Chemist and Nobel Laureate, Dr. Roger D. Kornberg, to Board of Directors Feb 29, 2016
